Cell-Based Targeting of Anti-Cancer Nanotherapy to Tumors
Department of Anatomy and Physiology, Kansas State University, Manhattan, KS66506, USA
- *Corresponding Author:
- Deryl Troyer
Department of Anatomy and Physiology
Kansas State University, Manhattan, KS66506, USA
E-mail: [email protected]
Received date: March 07, 2013; Accepted date: March 28, 2013; Published date: March 30, 2013
Citation: Troyer D (2013) Cell-Based Targeting of Anti-Cancer Nanotherapy to Tumors. J Cancer Sci Ther 5: 142-143. doi: 10.4172/1948-5956.1000200
Copyright: © 2013 Troyer D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
There is emerging and convincing data that certain cells, administered systemically, have a natural propensity to migrate to cancerous tissues in preclinical models. Examples of such cells include neural stem cells, bone marrow mesenchymal stem cells, umbilical cord Wharton’s jelly stem cells , and defensive cells.This homing ability can be exploited by using cells as stealth vehicles to ferry therapeutic nanomaterials to tumors to facilitate penetration, reduce potential toxicity, reduce potential unwanted immune consequences, and reduce removal by the reticuloendothelial system (RES).